Background: Automated bone scan index (aBSI) change (ΔBSI) after treatment and survival in men with prostate cancer remains unclear. We evaluated the correlation between ΔBSI after cabazitaxel and overall survival (OS) in men with bone metastatic castration-resistant prostate cancer (CRPC). Methods: We retrospectively enrolled 32 men with bone metastatic CRPC who had received cabazitaxel. The correlation between ΔBSI from baseline to 16 weeks after starting cabazitaxel and OS was analyzed by multivariate analysis. Results: Median age and time to CRPC were 70.7 years and 9.5 months, respectively. The median cycles of docetaxel before cabazitaxel were eight. Ten (31.2%) patients had visceral metastases at baseline. Median baseline prostate-specific antigen (PSA) was 123.0 ng/mL. The median aBSIs at baseline and 16 weeks after cabazitaxel were 3.2 and 4.4%, respectively. Improvements in aBSI and PSA after 16 weeks of cabazitaxel occurred in 7 (21.9%) and 12 patients (37.5%), respectively. There were no correlations between ΔBSI and OS (p = 0.55), but PSA change was significantly correlated with OS (p = 0.03) by multivariate analysis. Conclusions: This study demonstrated that ΔBSI from baseline to16 weeks after starting cabazitaxel was not correlated with OS among men with bone metastatic CRPC. Further prospective studies may be warranted to confirm the limited utility of aBSI in this setting.

Keywords:
Bone scan index, Cabazitaxel, Prostate cancer, Castration-resistant prostate cancer
1.
Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: The bone scan index.
Clin Cancer Res
. 1998 Jul;4(7):1765–72.
2.
Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
J Clin Oncol
. 2012 Feb;30(5):519–24.
3.
Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
Eur Urol
. 2012 Jul;62(1):78–84.
4.
Mitsui Y, Shiina H, Yamamoto Y, Haramoto M, Arichi N, Yasumoto H, et al. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer.
BJU Int
. 2012 Dec;110(11b 11 Pt B):E628–34.
5.
Kaboteh R, Damber JE, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, et al. Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy.
EJNMMI Res
. 2013 Feb;3(1):9.
6.
Kaboteh R, Gjertsson P, Leek H, Lomsky M, Ohlsson M, Sjöstrand K, et al. Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index.
EJNMMI Res
. 2013 Aug;3(1):64.
7.
Poulsen MH, Rasmussen J, Edenbrandt L, Hoilund-Carlsen PF, Gerke O, Johansen A, et al. Bone scan index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
BJU Int
. 2016 May;117(5):748–53.
8.
Sonpavde G, Bhor M, Hennessy D, Bhowmik D, Shen L, Nicacio L, et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based us oncology practices.
Clin Genitourin Cancer
. 2015 Aug;13(4):309–18.
9.
Miyoshi Y, Yoneyama S, Kawahara T, Hattori Y, Teranishi J, Kondo K, et al. Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.
BMC Cancer
. 2016 Feb;16(1):128.
10.
Reza M, Jones R, Aspegren J, Massard C, Mattila L, Mustonen M, et al. Bone scan index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received odm-201 in the arades multicentre study.
Eur Urol Focus
. 2016 Dec;2(5):547–52.
11.
Reza M, Ohlsson M, Kaboteh R, Anand A, Franck-Lissbrant I, Damber JE, et al. Bone scan index as an imaging biomarker in metastatic castration-resistant prostate cancer: A multicentre study based on patients treated with abiraterone acetate (zytiga) in clinical practice.
Eur Urol Focus
. 2016 Dec;2(5):540–6.
12.
Uemura K, Miyoshi Y, Kawahara T, Yoneyama S, Hattori Y, Teranishi J, et al. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.
BMC Cancer
. 2016 Feb;16(1):109.
13.
Li D, Lv H, Hao X, Dong Y, Dai H, Song Y. Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: a meta-analysis.
Oncotarget
. 2017 Jul;8(48):84449–58.
14.
Miyoshi Y, Uemura K, Kawahara T, Yoneyama S, Hattori Y, Teranishi JI, et al. Prognostic value of automated bone scan index in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Clin Genitourin Cancer
. 2017 Aug;15(4):472–8.
15.
Uemura K, Miyoshi Y, Kawahara T, Ryosuke J, Yamashita D, Yoneyama S, et al. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel.
BMC Cancer
. 2018 May;18(1):501.
16.
Zacho HD, Gade M, Mortensen JC, Bertelsen H, Boldsen SK, Barsi T, et al. Bone scan index is an independent predictor of time to castration-resistant prostate cancer in newly diagnosed prostate cancer: A prospective study.
Urology
. 2017 Oct;108:135–41.
17.
Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, et al. Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: A secondary analysis of a randomized clinical trial.
JAMA Oncol
. 2018 Jul;4(7):944–51.
18.
Koizumi M, Wagatsuma K, Miyaji N, Murata T, Miwa K, Takiguchi T, et al. Evaluation of a computer-assisted diagnosis system, BONENAVI version 2, for bone scintigraphy in cancer patients in a routine clinical setting.
Ann Nucl Med
. 2015 Feb;29(2):138–48.
19.
Nakajima K, Nakajima Y, Horikoshi H, Ueno M, Wakabayashi H, Shiga T, et al. Enhanced diagnostic accuracy for quantitative bone scan using an artificial neural network system: a Japanese multi-center database project.
EJNMMI Res
. 2013 Dec;3(1):83.
20.
Fosbol MO, Petersen PM, Kjaer A, Mortensen J. Radium-223 therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematological toxicity.
J Nucl Med
. 2018 Apr;59(4):596–602.
21.
Anand A, Morris MJ, Larson SM, Minarik D, Josefsson A, Helgstrand JT, et al. Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.
EJNMMI Res
. 2016 Dec;6(1):23.
22.
von Hardenberg J, Schwartz M, Werner T, Fuxius S, Strauss A, Worst TS, et al. Oncologic response and hospitalization rate of patients receiving cabazitaxel in the fourth-line and beyond in castration-resistant prostate cancer: analysis of a retrospective cohort and a structured literature review.
Urol Int
. 2017;99(4):414–21.
23.
Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ: Phase ii study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.
Clin Cancer Res
. 2011 Jul 15;17(14):4854–61.
24.
Liu Y, Zhao S, Wang J, Zhu Z, Luo L, Li E, et al. Serum neuroendocrine markers predict therapy outcome of patients with metastatic castration-resistant prostate cancer: A meta-analysis.
Urol Int
. 2019;102(4):373–84.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.